Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Next Previous
Trial Profile

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 24 Apr 2025 According to Kairos Pharma media release, CSO Dr. Neil Bhowmick's lab received $876,000 from the Department of Defense to support a biomarker study for lung cancer patients responsive to ENV105. The company is aiming to be able to discuss safety and interim efficacy results toward the end of the second quarter of 2025.
  • 05 Mar 2025 Planned End Date changed from 1 Jan 2026 to 1 Jan 2028.
  • 05 Mar 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top